TG Therapeutics' MS drug shows low relapse rate after six years

TG Therapeutics (TGTX) announced robust six-year Phase 3 data for its RMS drug, BRIUMVI, demonstrating sustained efficacy with a 0.012 annualized relapse rate and a consistent safety profile, which has contributed to a 52.6% stock return over the past year. Despite this strong clinical validation and Q2 2025 revenue exceeding forecasts, the company missed EPS estimates, and BofA Securities reiterated an "Underperform" rating, indicating mixed investor sentiment even as TGTX progresses a subcutaneous BRIUMVI trial and executes share repurchases.

Analysis

TG Therapeutics (TGTX) has presented robust six-year Phase 3 data for its multiple sclerosis drug, BRIUMVI, reinforcing its strong clinical profile. The study demonstrated a remarkably low annualized relapse rate of 0.012 and a consistent safety profile with no new signals, which has supported the stock's 52.6% return over the past year and the company's impressive 87% gross profit margin and 31% revenue growth. However, this positive clinical momentum is contrasted by mixed recent financial results. In Q2 2025, the company missed earnings per share estimates, posting $0.17 versus a $0.19 forecast, even as it beat revenue expectations with $141.1 million. This mixed performance, coupled with a reiterated "Underperform" rating from BofA Securities, suggests investor sentiment is not uniformly positive. The company is pursuing future growth by initiating a Phase 3 trial for a more convenient subcutaneous version of BRIUMVI and is supporting its stock through a new $100 million share repurchase program, signaling management confidence amidst the conflicting data points.

Key Decisions for Investors

• Investors should weigh the compelling long-term efficacy and safety data of BRIUMVI, which supports a strong growth narrative, against the immediate concerns raised by the Q2 earnings miss and the cautious 'Underperform' rating from BofA Securities.
• The initiation of a Phase 3 trial for a subcutaneous version of BRIUMVI represents a significant potential catalyst; its progress and eventual data should be monitored closely as it could materially impact the drug's market share and long-term value.
• Consider the dual signals of management executing a $100 million share buyback, suggesting internal confidence, while Briumvi's sales, though meeting consensus, failed to excite the market, indicating a need for stronger sales acceleration to justify further upside.